Distinct Comorbidity Clusters in Patients With Acute Heart Failure: Data From RELAX-AHF-2

JACC Heart Fail. 2024 Oct;12(10):1762-1774. doi: 10.1016/j.jchf.2024.04.028. Epub 2024 Jul 3.

Abstract

Background: Multimorbidity frequently occurs in patients with acute heart failure (AHF). The co-occurrence of comorbidities often follows specific patterns.

Objectives: This study investigated multimorbidity subtypes and their associations with clinical outcomes.

Methods: From the prospective RELAX-AHF-2 (Relaxin for the Treatment of Acute Heart Failure-2) trial, 6,545 patients (26% with HF with preserved ejection fraction, defined as LVEF ≥50%) were classified into multimorbidity groups using latent class analysis. The association between subgroups and clinical outcomes was examined. Validation of these findings was conducted in the RELAX-AHF trial, which comprised 1,161 patients.

Results: Five distinct multimorbidity groups emerged: 1) diabetes and chronic kidney disease (CKD) (often male, high prevalence of CKD and diabetes mellitus); 2) ischemic (ischemic HF); 3) elderly/atrial fibrillation (AF) (oldest, high prevalence of AF); 4) metabolic (obese, hypertensive, more often HF with preserved ejection fraction); and 5) young (fewest comorbidities). After adjusting for confounders, patients in the diabetes and CKD (HR: 1.80; 95% CI: 1.50-2.20), elderly/AF (HR: 1.42; 95% CI: 1.20-1.70), and metabolic (HR: 1.40; 95% CI: 1.20-1.80) groups had higher rates of the composite outcome than patients in the young group, primarily driven by differences in rehospitalization. Treatment allocation (placebo or serelaxin) modified these associations (Pinteraction <0.001). Serelaxin-treated patients in the young group were associated with a lower risk for all-cause mortality (HR: 0.59; 95% CI: 0.40-0.90). Similarly, patients from the RELAX-AHF trial clustered in 5 multimorbidity groups. The clinical characteristics and associations with outcomes could also be validated.

Conclusions: Comorbidities naturally clustered into 5 mutually exclusive groups in RELAX-AHF-2, showing variations in clinical outcomes. These data emphasize that the specific combination of comorbidities can influence adverse outcomes and treatment responses in patients with AHF.

Keywords: RELAX-AHF-2; acute heart failure; cluster; multimorbidity; poLCA.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Acute Disease
  • Aged
  • Aged, 80 and over
  • Atrial Fibrillation / complications
  • Atrial Fibrillation / drug therapy
  • Atrial Fibrillation / epidemiology
  • Comorbidity
  • Diabetes Mellitus / epidemiology
  • Female
  • Heart Failure* / drug therapy
  • Heart Failure* / epidemiology
  • Heart Failure* / physiopathology
  • Humans
  • Hypertension / drug therapy
  • Hypertension / epidemiology
  • Male
  • Middle Aged
  • Multimorbidity
  • Myocardial Ischemia / epidemiology
  • Prospective Studies
  • Recombinant Proteins / therapeutic use
  • Relaxin* / therapeutic use
  • Renal Insufficiency, Chronic / complications
  • Renal Insufficiency, Chronic / epidemiology
  • Stroke Volume / physiology

Substances

  • Relaxin
  • serelaxin protein, human
  • Recombinant Proteins